NASDAQ:MDGL

Madrigal Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy MDGL

*Your capital is at risk

$488.15

+35.29 (+7.79%)

At Close: Jun 03, 2026

Madrigal Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -71.10. In total, the insiders bought 159.04K and sold 51.92K MDGL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-71.10
● Buy	159.04K shares
● Sell	51.92K shares
24% Buy Activity Moderate Positive Correlation
Sell Signal High Confidence May 22, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -71.1. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (24% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	332 Value: $177.3K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	1 094 Value: $561.3K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	1 480 Value: $757.7K
Jan 09, 2026 Buy	Common Stock M-Exempt	Friedman Paul A Director	Director	24 520 Value: $387.4K
Jan 09, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Friedman Paul A Director	Director	280 Value: $4K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	280 Value: $154.3K
Jan 09, 2026 Buy	Common Stock M-Exempt	Friedman Paul A Director	Director	280 Value: $4K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	80 Value: $43.0K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	487 Value: $261.5K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	473 Value: $253.5K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	148 Value: $79.2K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	80 Value: $42.6K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	691 Value: $365.7K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	1 560 Value: $822.1K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	1 199 Value: $628.4K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	840 Value: $438.5K
Jan 09, 2026 Sell	Common Stock S-Sale	Taub Rebecca Director	Director	539 Value: $280.2K
Jan 09, 2026 Sell	Common Stock S-Sale	Taub Rebecca Director	Director	2 044 Value: $1.06M
Jan 09, 2026 Sell	Common Stock S-Sale	Taub Rebecca Director	Director	937 Value: $482.2K
Jan 09, 2026 Buy	Common Stock M-Exempt	Taub Rebecca Director	Director	18 410 Value: $290.9K
Jan 09, 2026 Sell	Common Stock S-Sale	Taub Rebecca Director	Director	40 Value: $21.8K
Jan 09, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Friedman Paul A Director	Director	24 520 Value: $387.4K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	480 Value: $258.8K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	1 345 Value: $692.2K
Jan 09, 2026 Sell	Common Stock S-Sale	Friedman Paul A Director	Director	1 996 Value: $1.03M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT MADRIGAL PHARMACEUTICALS, INC.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745,...

Read Full Profile Here